20 completed, 6 recruiting, 4 terminated, 4 withdrawn. 26 Phase 2, 14 Phase 1, 4 Phase 3, 3 Not applicable.
Follow Dermatofibrosarcoma: new trials by email Literature Review of Dermatofibrosarcoma trials Research Report on Dermatofibrosarcoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Exploratory Study on Toripalimab and Anlotinib Combined With Standard Chemotherapy for Refractory Dermatofibrosarcoma Protuberans Toripalimab, Anlotinib, Standard Chemotherapy - Dermatofibrosarcoma Protuberans (DFSP) | Phase 2 | Not yet recruiting | Yanjie Zhang, MD | 20 | 2026-06-15 | 2026-06-16 |
| Dose-escalated, Hypofractionated, Definitive Proton Radiotherapy for Patients With Inoperable Soft Tissue Sarcoma. Definitive radiotherapy - Soft Tissue Sarcoma (STS), Soft Tissue Sarcoma Adult | Phase 2 | Recruiting | Oslo University Hospital | 40 | 2026-01-26 | 2026-01-28 |
| Hypofractionated, 3-week, Preoperative Proton or X-ray Radiotherapy for Patients With Localized Soft Tissue Sarcoma preoperative, Quality of life, Functional outcome - Soft Tissue Sarcoma (Excluding GIST), Soft Tissue Sarcoma Adult | Phase 2 | Recruiting | Oslo University Hospital | 110 | 2026-01-26 | 2026-01-28 |
| Evaluation of Chest CT Versus Chest X-Ray for Lung Surveillance After Curative-Intent Resection of High-Risk Truncal-Extremity Soft Tissue Sarcoma Biopsy, Chest Computed Tomography, Chest Radiography - Adult Pleomorphic Rhabdomyosarcoma, AJCC Grade 2 Sarcoma | Not applicable | Not yet recruiting | ECOG-ACRIN Cancer Research Group | 1582 | 2025-01-28 | 2024-07-30 |
| A Phase 1, First-in-human Study of OKN4395 and Pembrolizumab in Patients With Solid Tumors OKN4395, Pembrolizumab, Fasting - Solid Tumours, Sarcoma | Phase 1 | Recruiting | Epkin | 146 | 2025-01-23 | 2026-06-11 |
| NIFR Image-guided Surgery for Malignant Soft Tissue Tumor With Low-dose SWIG Technique ICG administration - Dermatofibrosarcoma Protuberans (DFSP), Skin Squamous Cell Carcinoma | Phase 1 | Not yet recruiting | The Plastic Surgery Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College | 592 | 2024-10-30 | 2024-09-24 |
| Brightline-3: A Study to Find Out Whether Brigimadlin in Combination With Ezabenlimab Helps People With Advanced Soft Tissue Sarcoma Brigimadlin, Ezabenlimab, Gemcitabine - Advanced Soft Tissue Sarcoma, Undifferentiated Pleomorphic Sarcoma (UPS) | Phase 3 | Withdrawn | Boehringer Ingelheim | 2024-06-27 | 2024-07-17 | |
| NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS) Surgical resection, Proton beam radiation therapy, Pazopanib - Adipocytic Neoplasm, Liposarcoma | Phase 1 / Phase 2 | Recruiting | St. Jude Children's Research Hospital | 139 | 2024-03-27 | 2026-08-03 |
| Testing Low-Dose Common Chemotherapy (Liposomal Doxorubicin) in Combination With an Anti-Cancer Drug, Peposertib, in Advanced Sarcoma Biopsy Procedure, Biospecimen Collection, Computed Tomography - Metastatic Dedifferentiated Liposarcoma, Metastatic Leiomyosarcoma | Phase 1 | Recruiting | National Cancer Institute (NCI) | 30 | 2024-02-06 | 2026-11-04 |
| Phase 2 Study of 9-ING-41 With Chemotherapy in Sarcoma Gemcitabine, 9-ING-41, Docetaxel - Soft Tissue Sarcoma, Undifferentiated Pleomorphic Sarcoma | Phase 2 | Withdrawn | Brown University | 2022-03-01 | 2021-12-07 | |
| A Phase 2 Study of 9-ING-41Combined With Chemotherapy in Adolescents and Adults With Advanced Sarcomas Gemcitabine, Docetaxel, 9-ING-41 - Sarcoma, Soft Tissue Sarcoma | Phase 2 | Withdrawn | Brown University | 2021-09-01 | 2021-07-28 | |
| A Study to Learn About the Study Medicine (Called Ontorpacept or TTI-621) Given Alone and in Combination With Doxorubicin in People With Leiomyosarcoma Ontorpacept (TTI-621), Doxorubicin - Leiomyosarcoma | Phase 2 | Terminated | Pfizer | 76 | 2021-06-22 | 2024-12-11 |
| ENVASARC: Envafolimab And Envafolimab With Ipilimumab In Patients With Undifferentiated Pleomorphic Sarcoma Or Myxofibrosarcoma Envafolimab, Ipilimumab - Undifferentiated Pleomorphic Sarcoma, Myxofibrosarcoma | Phase 2 | Unknown | Tracon Pharmaceuticals Inc. | 207 | 2020-12-09 | 2024-05-17 |
| Nivolumab and BO-112 Before Surgery for the Treatment of Resectable Soft Tissue Sarcoma Definitive Surgical Resection, Nanoplexed Poly I:C BO-112, Nivolumab - Leiomyosarcoma, Malignant Peripheral Nerve Sheath Tumor | Phase 1 | Active not recruiting | Jonsson Comprehensive Cancer Center | 14 | 2020-10-14 | 2026-03-10 |
| A Study of Pembrolizumab Plus Local Chemotherapy Using Isolated Limb Infusion (ILI) for Patients With Sarcoma in the Arm or Leg Isolated Limb Infusion, Pembrolizumab, infusion of melphalan and dactinomycin - Sarcoma, Myxofibrosarcoma | Phase 2 | Recruiting | Memorial Sloan Kettering Cancer Center | 30 | 2020-04-01 | 2026-04-23 |
| Study of DCC-3014 in Combination With Avelumab in Patients With Advanced or Metastatic Sarcomas DCC-3014, Avelumab - Sarcoma, Advanced Sarcoma | Phase 1 | Completed | Memorial Sloan Kettering Cancer Center | 32 | 2020-01-22 | 2025-08-28 |
| Treatment of Dermatofibrosarcoma Protuberans in Patients 10 Years and Younger MOHS micrographic surgery, Wide local excision - Dermatofibrosarcoma Protuberans | Not applicable | Completed | Mayo Clinic | 7 | 2018-07-01 | 2020-08-05 |
| CAB-AXL-ADC Safety and Efficacy Study in Adult and Adolescent Patients With Sarcoma CAB-AXL-ADC, PD-1 inhibitor - Undifferentiated Pleomorphic Sarcoma, Myxofibrosarcoma | Phase 1 / Phase 2 | Completed | BioAtla, Inc. | 245 | 2018-02-15 | 2025-09-23 |
| Ribociclib and Doxorubicin in Treating Patients With Metastatic or Advanced Soft Tissue Sarcomas That Cannot Be Removed by Surgery Doxorubicin Hydrochloride, Laboratory Biomarker Analysis, Pharmacological Study - Advanced Soft Tissue Sarcoma, Locally Advanced Angiosarcoma | Phase 1 | Completed | OHSU Knight Cancer Institute | 16 | 2017-03-10 | 2023-08-16 |
| Hypofractionated Radiotherapy With Sequential Chemotherapy in Marginally Resectable Soft Tissue Sarcomas of Extremities or Trunk Wall Sequential chemotherapy - 3 courses of AI, Hypofractionated radiotherapy - Sarcoma, Fibrosarcoma | Phase 2 | Unknown | Maria Sklodowska-Curie National Research Institute of Oncology | 46 | 2017-02-11 | 2021-01-22 |
Showing 20 of 41. Sign in to see all of them.
Sarcoma (28) · Histiocytoma, Malignant Fibrous (26) · Liposarcoma (23) · Leiomyosarcoma (22) · Sarcoma, Synovial (18) · Fibrosarcoma (16) · Neurofibrosarcoma (15) · Hemangiosarcoma (14) · Chondrosarcoma, Extraskeletal Myxoid (8) · Rhabdomyosarcoma (8) · Malignant mesenchymal tumor (7) · Osteosarcoma (7) · Sarcoma, Alveolar Soft Part (7) · Chondrosarcoma (5)
Neoplasms by Histologic Type (41) · Neoplasms, Connective Tissue (41) · Neoplasms, Connective and Soft Tissue (41) · Neoplasms, Fibrous Tissue (41) · Neoplasms (38) · Histiocytoma (26) · Fibrosarcoma (25) · Neoplasms, Muscle Tissue (25) · Neoplasms, Adipose Tissue (22) · Neoplasms, Nerve Tissue (19) · Nervous System Diseases (15) · Nervous System Neoplasms (15) · Neurofibroma (15) · Neuromuscular Diseases (15) · Peripheral Nervous System Diseases (15)
Doxorubicin (9) · Imatinib Mesylate (6) · Ifosfamide (4) · pazopanib (4) · Docetaxel (3) · Gemcitabine (3) · Radiotherapy (3) · 3-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-(1,3)dioxolo(4,5-f)indol-7-yl)-pyrrole-2,5-dione (2) · Biopsy (2) · Mohs Surgery (2) · Neoadjuvant Therapy (2) · Radiation (2) · pembrolizumab (2) · 130-nm albumin-bound paclitaxel (1) · 2,2-dimethyl-N-(6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-N'-(2,2,3,3,3-pentafluoropropyl)malonamide (1)
National Cancer Institute (NCI) (8) · Memorial Sloan Kettering Cancer Center (3) · Brown University (2) · Children's Oncology Group (2) · Novartis Pharmaceuticals (2) · Oslo University Hospital (2) · Assistance Publique - Hôpitaux de Paris (1) · BioAtla, Inc. (1) · Boehringer Ingelheim (1) · Celgene (1) · Centre Oscar Lambret (1) · City of Hope Medical Center (1) · Dermatologic Cooperative Oncology Group (1) · ECOG-ACRIN Cancer Research Group (1) · Epkin (1)
United States (26) · Canada (4) · France (4) · United Kingdom (4) · Australia (3) · Spain (3) · Norway (2) · Puerto Rico (2) · Switzerland (2) · Austria (1) · Belgium (1) · Denmark (1) · Germany (1) · Hong Kong (1) · Ireland (1)
Ivar Hompland, MD, PhD (2) · Kjetil Boye, MD, PhD (2) · Aaron R Weiss (1) · Andrea Ferrari, MD (1) · Bernadette Brennan, MD (1) · Bradley D DeNardo, MD (1) · Bradley DeNardo, MD (1) · Brian A Van Tine, M.D., Ph.D. (1) · Candace L Haddox (1) · Charles Theuer, MD, PhD (1) · Dirk Schadendorf, MD (1) · Don S Dizon, MD (1) · Donna L. Betcher, RN, MSN (1)
PMID 19451429, PMID 19451433, PMID 25858498, PMID 27502708, PMID 28391003, PMID 30954717, PMID 31401903, PMID 31786124, PMID 32554315, PMID 32702309, PMID 32827353, PMID 32956651, PMID 33548339, PMID 34515544, PMID 34623899, PMID 34722269, PMID 36566574, PMID 37523624, PMID 38579194, PMID 38757485, PMID 41386267, PMID 42194972
P30CA008748 (2), U10CA098543 (2), U10CA180821 (2), 2008 (1), 2009 (1), K08CA245181 (1), N01CM00071 (1), N01CM62203 (1), N01CM62206 (1), P30CA014599 (1), P30CA033572 (1), U01CA069856 (1), U10CA031946 (1), U10CA032102 (1), U10CA180830 (1)